In order to obtain higher conversion efficiency and to reduce production cost for hydrogenated amorphous silicon/crystalline silicon(a-Si:H/c-Si) based heterojunction solar cells, an a-Si:H/c-Si heterojunction with lo...In order to obtain higher conversion efficiency and to reduce production cost for hydrogenated amorphous silicon/crystalline silicon(a-Si:H/c-Si) based heterojunction solar cells, an a-Si:H/c-Si heterojunction with localized p–n structure(HACL) is designed. A numerical simulation is performed with the ATLAS program. The effect of the a-Si:H layer on the performance of the HIT(heterojunction with intrinsic thin film) solar cell is investigated. The performance improvement mechanism for the HACL cell is explored. The potential performance of the HACL solar cell is compared with those of the HIT and HACD(heterojunction of amorphous silicon and crystalline silicon with diffused junction) solar cells.The simulated results indicate that the a-Si:H layer can bring about much absorption loss. The conversion efficiency and the short-circuit current density of the HACL cell can reach 28.18% and 43.06 m A/cm^2, respectively, and are higher than those of the HIT and HACD solar cells. The great improvement are attributed to(1) decrease of optical absorption loss of a-Si:H and(2) decrease of photocarrier recombination for the HACL cell. The double-side local junction is very suitable for the bifacial solar cells. For an HACL cell with n-type or p-type c-Si base, all n-type or p-type c-Si passivating layers are feasible for convenience of the double-side diffusion process. Moreover, the HACL structure can reduce the consumption of rare materials since the transparent conductive oxide(TCO) can be free in this structure. It is concluded that the HACL solar cell is a promising structure for high efficiency and low cost.展开更多
This prospective,nonrandomized,open-label phase 2 trial(Chinese Clinical Trial Registry,ChiCTR2200061906)aimed to evaluate the effectiveness of adding the PD-1 antibody tislelizumab to perioperative chemotherapy in pa...This prospective,nonrandomized,open-label phase 2 trial(Chinese Clinical Trial Registry,ChiCTR2200061906)aimed to evaluate the effectiveness of adding the PD-1 antibody tislelizumab to perioperative chemotherapy in patients with locally advanced gastroesophageal junction adenocarcinoma(GEJA).This study enrolled patients with GEJA clinically staged as cT3-4aNanyM0 or cT1-2N+M0 from October 2022 to June 2023.Eligible patients were administered three preoperative and five postoperative 3-week cycles of treatment with PD-1 antibody tislelizumab plus SOX(S-1 and oxaliplatin)regimen.The primary endpoint was major pathological response(MPR)rate.Thirty-two patients were enrolled.The median age was 60 years(range:28–74 years),and 53.1%(17/32)patients were Siewert Ⅲ type.All patients received at least one cycle of assigned preoperative treatment,and 93.8%(30/32)patients completed three cycles of assigned preoperative tislelizumab and SOX.The R0 resection rate was 96.9%(31/32).MPR,pathological complete response(pCR)of primary tumors and ypT0N0 rates were 50.0%(16/32,95%CI:31.9-68.1%),28.1%(9/32,95%CI:13.7-46.7%)and 25.0%(8/32,95%CI:11.5-43.4%),respectively.The surgical morbidity rate was 15.6%(5/32),and no 30-day mortality was observed.In the preoperative and postoperative treatment periods,the rate of treatment-related grade 3-4 adverse events was 31.2%(10/32).At the date of 7th Jan 2025,8(25.0%)patients occurred recurrence.Therefore,perioperative tislelizumab plus chemotherapy demonstrated significantly improved pathological regression and might be a promising option for patients with locally advanced resectable GEJA.展开更多
基金Project supported by the National Key R&D Program of China(Grant No.2018YFB1500403)the National Natural Science Foundation of China(Grant Nos.11964018,61741404,and 61464007)the Natural Science Foundation of Jiangxi Province of China(Grant No.20181BAB202027)
文摘In order to obtain higher conversion efficiency and to reduce production cost for hydrogenated amorphous silicon/crystalline silicon(a-Si:H/c-Si) based heterojunction solar cells, an a-Si:H/c-Si heterojunction with localized p–n structure(HACL) is designed. A numerical simulation is performed with the ATLAS program. The effect of the a-Si:H layer on the performance of the HIT(heterojunction with intrinsic thin film) solar cell is investigated. The performance improvement mechanism for the HACL cell is explored. The potential performance of the HACL solar cell is compared with those of the HIT and HACD(heterojunction of amorphous silicon and crystalline silicon with diffused junction) solar cells.The simulated results indicate that the a-Si:H layer can bring about much absorption loss. The conversion efficiency and the short-circuit current density of the HACL cell can reach 28.18% and 43.06 m A/cm^2, respectively, and are higher than those of the HIT and HACD solar cells. The great improvement are attributed to(1) decrease of optical absorption loss of a-Si:H and(2) decrease of photocarrier recombination for the HACL cell. The double-side local junction is very suitable for the bifacial solar cells. For an HACL cell with n-type or p-type c-Si base, all n-type or p-type c-Si passivating layers are feasible for convenience of the double-side diffusion process. Moreover, the HACL structure can reduce the consumption of rare materials since the transparent conductive oxide(TCO) can be free in this structure. It is concluded that the HACL solar cell is a promising structure for high efficiency and low cost.
基金supported by the Noncommunicable Chronic Diseases-National Science and Technology Major Project(2023ZD0501500 to SQY)National Natural Science Foundation of China(82103586,to RCN,82473358 to SQY)+1 种基金Beijing Xisike Clinical Oncology Research Foundation(Y-HR2022MS-0324,to SQY,Y-2023AZMETQN-0017to RCN,Y-2022METAZMS-0123to YFL)the Guangdong Esophageal Cancer Institute Science and Technology Program(M202210).
文摘This prospective,nonrandomized,open-label phase 2 trial(Chinese Clinical Trial Registry,ChiCTR2200061906)aimed to evaluate the effectiveness of adding the PD-1 antibody tislelizumab to perioperative chemotherapy in patients with locally advanced gastroesophageal junction adenocarcinoma(GEJA).This study enrolled patients with GEJA clinically staged as cT3-4aNanyM0 or cT1-2N+M0 from October 2022 to June 2023.Eligible patients were administered three preoperative and five postoperative 3-week cycles of treatment with PD-1 antibody tislelizumab plus SOX(S-1 and oxaliplatin)regimen.The primary endpoint was major pathological response(MPR)rate.Thirty-two patients were enrolled.The median age was 60 years(range:28–74 years),and 53.1%(17/32)patients were Siewert Ⅲ type.All patients received at least one cycle of assigned preoperative treatment,and 93.8%(30/32)patients completed three cycles of assigned preoperative tislelizumab and SOX.The R0 resection rate was 96.9%(31/32).MPR,pathological complete response(pCR)of primary tumors and ypT0N0 rates were 50.0%(16/32,95%CI:31.9-68.1%),28.1%(9/32,95%CI:13.7-46.7%)and 25.0%(8/32,95%CI:11.5-43.4%),respectively.The surgical morbidity rate was 15.6%(5/32),and no 30-day mortality was observed.In the preoperative and postoperative treatment periods,the rate of treatment-related grade 3-4 adverse events was 31.2%(10/32).At the date of 7th Jan 2025,8(25.0%)patients occurred recurrence.Therefore,perioperative tislelizumab plus chemotherapy demonstrated significantly improved pathological regression and might be a promising option for patients with locally advanced resectable GEJA.
